Analyzing SAGE Therapeutics (SAGE) and Cellular Dynamics International (ICEL)

SAGE Therapeutics (NASDAQ: SAGE) and Cellular Dynamics International (NASDAQ:ICEL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

This table compares SAGE Therapeutics and Cellular Dynamics International’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SAGE Therapeutics N/A N/A -$158.98 million ($6.87) -23.85
Cellular Dynamics International N/A N/A N/A ($1.94) -8.53

SAGE Therapeutics is trading at a lower price-to-earnings ratio than Cellular Dynamics International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for SAGE Therapeutics and Cellular Dynamics International, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SAGE Therapeutics 1 1 12 0 2.79
Cellular Dynamics International 0 0 0 0 N/A

SAGE Therapeutics currently has a consensus target price of $171.21, indicating a potential upside of 4.49%. Given SAGE Therapeutics’ higher possible upside, equities analysts plainly believe SAGE Therapeutics is more favorable than Cellular Dynamics International.

Profitability

This table compares SAGE Therapeutics and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SAGE Therapeutics N/A -89.46% -78.94%
Cellular Dynamics International -88.12% -57.59% -38.09%

Insider and Institutional Ownership

87.3% of SAGE Therapeutics shares are held by institutional investors. 6.1% of SAGE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SAGE Therapeutics beats Cellular Dynamics International on 5 of the 9 factors compared between the two stocks.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply